Axogen
From Wikipedia, the free encyclopedia
Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida.[1] Axogen products are designed to remedy peripheral nerve damage.[2][3][4] In 2013 the company raised $18 million in its initial public offering (IPO).[5] Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes.[6] The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
| |
| Nasdaq: AXGN Russell 2000 Component | |
| Founded | 1 January 2002  |
| Headquarters | United States |
As of 2019, Axogen was the only commercially available allograft approved by the Food and Drug Administration (FDA) for clinical use.[citation needed]
